Compare BridgeBio Pharma Inc (BBIO) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Teradyne, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Teradyne, Inc. trades at $359 (market cap $55.30B). The key difference: Teradyne, Inc. is far larger — about 3.4× BridgeBio Pharma Inc's market cap, and Teradyne, Inc. pays a 0.15% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TER | |
|---|---|---|
Market Cap | $16.46B | $55.30B |
Sector | Health | Technology |
52-Week High | $90.17 | $483.84 |
52-Week Low | $44.81 | $90.15 |
Enterprise Value | $18.02B | $55.13B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Teradyne (TER) trades at $341.11, down 5.14% over 24 hours, with a bearish technical signal. The stock shows strong fundamentals with three consecutive quarterly earnings beats and robust profitability margins. Recent news highlights AI-driven demand boosting semiconductor testing revenue, positioning TER as a key player in robotics and AI infrastructure. Cash flow trends indicate consistent operational strength despite negative net cash flow from aggressive investing activities.
Outlook remains positive with a consensus price target of $453.60, implying 33% upside. Risks include high valuation multiples and semiconductor cycle volatility. Analyst sentiment is strongly bullish with 64.5% buy ratings, supported by expanding AI and data center markets driving long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
